A Bifidobacterium-based synbiotic was well tolerated and increased colonization of administered strains in infants and toddlers.
|Articles|March 13, 2019
March 2019 Digital Edition
Advertisement
This month Contemporary Pediatrics brings you the latest on severe asthma, congenital limb deficiency, what to do when you’re sued for malpractice, and whether supplements can help with depression.
Advertisement
Related to this article
Pediatricians can help teen athletes navigate sports supplements by prioritizing nutrition and identifying products to support, limit, or avoid.
Semaglutide plus lifestyle changes moved 40.4% of children below the obesity threshold at 68 weeks in the phase 3 STEP Young trial.
Persephone's ARTEMIS trial found its Bifidobacterium-HMO synbiotic safe and effective at gut colonization in 114 infants and toddlers.
A content analysis of 159 picture books found food often symbolized family connection and culture more than nutrition alone, according to Carol Duh-Leong, MD, MPP.
The AAP's updated clinical report revises screening timelines, ferritin thresholds, and treatment protocols for pediatric iron deficiency and iron deficiency anemia.
A microbial metabolite, isovalerate, and its precursor leucine restored gut barrier function in malnourished mice, a preclinical study found.
A meta-analysis of 190 studies and 2.8 million children pinpoints eczema, delayed allergens, and antibiotics as top food allergy risks.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Updated AAP guidance changes iron deficiency screening and treatment in children
2
FDA approves rebisufligene etisparvovec, first gene therapy for Sanfilippo syndrome type A
3
Pegcetacoplan reduces proteinuria, stabilizes kidney function in adolescents with C3G and IC-MPGN
4
Tezepelumab meets co-primary and secondary endpoints in phase 3 eosinophilic esophagitis trial
5